Synaptogenix, Inc. (NASDAQ:SNPX – Get Rating) shares dropped 6.2% during mid-day trading on Tuesday . The stock traded as low as $5.90 and last traded at $6.10. Approximately 80,249 shares traded hands during trading, a decline of 29% from the average daily volume of 112,798 shares. The stock had previously closed at $6.50.
Separately, Maxim Group initiated coverage on shares of Synaptogenix in a research note on Tuesday, April 12th. They set a “buy” rating and a $14.00 target price on the stock.
The business’s 50 day simple moving average is $6.19 and its 200 day simple moving average is $7.66.
Synaptogenix Company Profile (NASDAQ:SNPX)
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
- Get a free copy of the StockNews.com research report on Synaptogenix (SNPX)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.